INTRODUCTION {#S1}
============

Joubert syndrome is a genetically heterogeneous ciliopathy characterized by intellectual disability, hypotonia, facial dysmorphism, retinal dystrophy, cystic kidney disease and molar tooth sign.^[@R1]^ Pathogenic variants in 37 genes are known to be associated with Joubert syndrome. Recently, using genome wide siRNA knockdown and exome sequencing, Wheway *et al.* identified recessive mutations in *PIBF1* in seven patients with Joubert syndrome 33 (MIM \#213300).^[@R2]^ Here, we report a subject with Joubert syndrome harboring a novel biallelic in-frame insertion of 36-bp in exon 9 of *PIBF1*.

METHODOLOGY {#S2}
===========

Clinical summary {#S3}
----------------

A two-years-old girl was evaluated for global developmental delay. She was born to consanguineous couple by cesarean section ([Fig 1A](#F1){ref-type="fig"}). She weighed 2.25 kg (−1 SD) at birth. Ventriculomegaly was noted on antenatal ultrasonography at 16 weeks of gestation. She had delayed cry at birth and an episode of seizure on first day of life. She received intensive neonatal care for first six days. She had feeding difficulties in the neonatal period. She could stand with support, followed simple commands and had minimal non-verbal communication skills at age two years. The couple's first child had succumbed to congenital diaphragmatic hernia.

At age two years, she had a height of 84 cm (1 SD), weight of 8.2 kg (−4 SD) and occipito-frontal circumference of 47 cm (1 SD). She had frontal prominence, deep-set eyes and midface retrusion ([Fig 1B, 1C](#F1){ref-type="fig"}). She had hypotonia and absent deep tendon reflexes. She had an enlarged liver extending 3 cm below right costal margin. She had acute renal failure at two years of age with elevated blood urea (71 mg/dL; normal range: 10--45 mg/dL) and creatinine (3.2 mg/dL; normal range: 0.6--45 mg/dL). Enlarged kidneys with increased cortical echogenicity and blurred cortico-medullary differentiation with mild ascites were noted by ultrasonography. Renal biopsy revealed periglomerular fibrosis, tubular atrophy, luminal hyaline casts and interstitial inflammation suggesting nephronophthisis. Chest radiograph was unremarkable ([Fig S1](#SD1){ref-type="supplementary-material"}). Micturating cystourethrogram showed grade IV vesicoureteric reflux. Echocardiography returned normal results. Magnetic resonance imaging of brain revealed polymicrogyria in right fronto-parieto-temporal and perisylvian region with thin splenium of corpus callosum and molar tooth sign ([Fig 1D, 1E, 1F](#F1){ref-type="fig"}). Ophthalmology evaluation showed hypermetropia. Urine analysis was unremarkable. Written informed consent was obtained from the participants. This study has the approval of institutional ethics committee.

Mutation analysis {#S4}
-----------------

DNA was extracted from leukocytes by conventional phenol-chloroform method. Chromosomal microarray was performed using Affymetrix Cytoscan 750K platform (Santa Clara, CA, US) and analyzed using Chromosome Analysis Suite (ChAS) software package (Affymetrix, USA). A commercially available ciliopathy panel was used to test 29 genes ([supplementary note](#SD1){ref-type="supplementary-material"}; *PIBF1* was not a part of this panel as it was discovered recently). Exome sequencing was done using Illumina's Nextera Rapid Capture Exome Kit on the Illumina NextSeq Platform (Illumina, San Diego, California, USA). The average coverage depth was 130x, with \~95% of the bases covered at \>20x, and a sensitivity of \>90%. Data were stored and analyzed using a previously-published automated pipeline, SeqMule v1.2.5.^[@R3]^ The variant call format (.vcf) file was annotated by ANNOVAR v.2016Feb01.^[@R4]^ The strategy used for the variant filtering is described in the [Table S1](#SD1){ref-type="supplementary-material"}. Candidate variants were validated and segregation analysis was carried out by Sanger sequencing. Genes implicated in the molecular mechanisms characterizing ciliary function and associated with ciliopathies (n=303, [Table S4](#SD1){ref-type="supplementary-material"}), were included from the SYSCILIA consortium gold standard (SCGSv1).^[@R5]^ Genotyping was carried out using Devyser Compact V3 QF-PCR kit and analyzed by GeneMarker software v.2.4.0. *In-silico* tools were used to predict the effect of candidate variants. The phenotypic information and the variant details can be accessed at ClinVar (Accession ID- SCV000583465.2)

RESULTS {#S5}
=======

Clinical findings in the proband suggested the diagnosis of Joubert syndrome. Autosomal recessive inheritance pattern was inferred from the pedigree. Next generation sequencing panel for ciliopathies was non-diagnostic. Only 45 rare variants remained after filtering the exome data for exonic, splicing, and homozygous variants ([Table S1](#SD1){ref-type="supplementary-material"} and [Table S2](#SD1){ref-type="supplementary-material"}). The variant, NM_006346.2, c.1181_1182insGCTTCGCAGATTGAAAACCAACCAAGAAATTGATCA, p.(Gln394_Leu395ins12) in *PIBF1* was observed in homozygous state in the proband and parents were heterozygous carriers ([Fig 2](#F2){ref-type="fig"}). This variant in *PIBF1* appeared as a discrete and significant increase in the read number on Integrative Genomics Viewer (IGV) ([Fig S2](#SD1){ref-type="supplementary-material"}).^[@R6]^ This variant is not observed in 1000 Genomes Project, ESP, gnomAD and in our in-house exome data of 357 individuals.^[@R7],\ [@R8]^ The variant is predicted to have damaging effects on the protein by PROVEAN (−17.967), PaPI (0.783), SIFT Indels 2 (0.858) and Human Splicing Finder (Alteration of an exonic ESE site).^[@R9]--[@R12]^ Father was homozygous for the candidate variants in *IFT27*, *CELSR1* and *TTLL6.* All the four candidate variants evaluated were in the regions of homozygosity as determined by chromosomal microarray ([Table S3](#SD1){ref-type="supplementary-material"}). We carried out genotyping by QF-PCR in the proband and the parents to rule out the possibility of sample mix-up as all the three rare candidate variants were observed in homozygous state in the father. The alleles segregated and possibility of sample mix-up was ruled out in the family.

DISCUSSION {#S6}
==========

We evaluated a consanguineous family with a two-years-old girl with global developmental delay, facial dysmorphism, hypotonia, polymicrogyria and molar tooth sign on brain imaging. Exome sequencing revealed a novel 36-bp insertion in exon 9 of *PIBF1* as the likely cause of the condition. Pathogenic variants in *PIBF1* have recently been reported in seven patients from five families including four Hutterite families ([Table 1](#T1){ref-type="table"}). All the earlier reported patients presented with global developmental delay, hypotonia and ataxia. Ataxia could not be assessed in the proband in our study. Cystic kidney disease and retinal dystrophy were noted in the proband. The characteristic molar tooth sign on brain imaging was observed in five families including ours, while it was absent in two patients in a single family. In addition to this, our patient also had perisylvian polymicrogyria and hypoplastic corpus callosum.^[@R2]^

The gene, *PIBF1*, encodes a protein that is produced during pregnancy in response to progesterone. PIBF1 is a core component of the human centrosome and is crucial for the accumulation of centriolar satellites, eventually forming the primary cilia.^[@R1]^ Depletion of PIBF1 is known to cause mitotic arrest, misaligned chromosomes, spindle pole fragmentation. A whole-genome siRNA reverse genetics screen for defects in biogenesis and maintenance of the primary cilium, combined with exome sequencing data identified recessive mutations in *PIBF1* in seven individuals with Joubert syndrome.^[@R2]^ Also, exogenous expression of human wild-type PIBF1 following siRNA knockdown was found to rescue ciliogenesis in mIMCD3 cells.

The pathogenic variants previously identified in *PIBF1* include two missense and a truncating variant ([Table 1](#T1){ref-type="table"}). The biallelic 36-bp insertion in *PIBF1* identified in our proband is predicted to have a damaging effect on the protein by in-silico tools.^[@R2]^ Further analysis for the effect of this variant on protein function could not be done as a suitable template for reliable protein modeling is unavailable at present. Also, reluctance of the family to participate in further functional studies hindered validation of the variant as a loss-of-function allele.

In conclusion, our report validates *PIBF1* as a causative gene for Joubert syndrome and expands the clinical and molecular spectrum of the condition. However, identification of additional variants in *PIBF1* and further functional validation are warranted for elucidation of the underlying pathogenic mechanism.
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======================
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![Pedigree (A). Proband at age 2 years has frontal prominence, deep set eyes and midface hypoplasia (B, C). Magnetic resonance imaging of brain revealed thickening and lengthening of superior cerebellar peduncle (arrow head shows molar tooth sign, D), prominent cerebrospinal fluid space (asterix, D, E), thinning of corpus callosum (arrow, E), and perisylvian polymicrogyria (black arrow, F).](nihms958880f1){#F1}

![Sanger chromatograms show the variant, c.1181_1182insGCTTCGCAGATTGAAAACCAACCAAGAAATTGATCA in *PIBF1* in homozygous state in proband (upper panel) and heterozygous state in father (middle panel) and mother (lower panel).](nihms958880f2){#F2}

###### 

Summary of clinical features and variants observed in patients with Joubert syndrome 33

                                      Current study            Wheway et al. 2015                                                                                     
  ----------------------------------- ------------------------ -------------------------------- ------------- ------------- ------------- ------------- ------------- -------------
  **Developmental delay**             \+                       \+                               \+            \+            \+            \+            \+            \+
  **Hypotonia**                       \+                       \+                               \+            \+            \+            \+            \+            \+
  **Ataxia**                          NA                       \+                               \+            \+            \+            \+            \+            \+
  **Cystic kidney disease**           \+                       NA                               NA            NA            NA            NA            NA            NA
  **Retinal degeneration**            −                        NA                               NA            NA            NA            NA            NA            NA
  **Molar tooth sign**                \+                       \+                               −             −             NA            \+            \+            \+
  **Perisylvian polymicrogyria**      \+                       −                                −             −             −             −             −             −
  **Hypoplasia of corpus callosum**   \+                       −                                −             −             −             −             −             −
  **Vermian hypoplasia**              \+                       \+                               \+            \+            NA            \+            \+            \+
  **Foramen magnum cephalocele**      −                        NA                               −             −             NA            −             −             \+
  **cDNA change**                     c.1181_1182ins36         c.1214G\>A, c.1669delC           c.1910A\>C    c.1910A\>C    c.1910A\>C    c.1910A\>C    c.1910A\>C    c.1910A\>C
  **Protein change**                  p.(Gln394_Leu395ins12)   p.Arg405Gln, p.Leu557Phefs\*18   p.Asp637Ala   p.Asp637Ala   p.Asp637Ala   p.Asp637Ala   p.Asp637Ala   p.Asp637Ala

Abbreviations: + present, − absent, NA not available
